Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Michigan

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical treatments and their potential risks. Within this broad context, the transition from broad health education to specific occupational exposure concerns requires a careful shift in focus. Historically, health information dissemination has emphasized the benefits and general side effects of pharmaceuticals, but as scientific inquiry deepens, attention increasingly turns to the real-world implications of long-term medication use. This is particularly relevant when considering therapies that carry known, albeit rare, adverse events. In the domain of mass production, where consistency and patient access are paramount, the need to bridge general awareness with specific risk scenarios becomes critical. One such scenario involves the exposure to Tysabri, a medication used for certain chronic conditions, and its association with Progressive Multifocal Leukoencephalopathy (PML). While general health information may have initially highlighted the drug’s efficacy, the occupational and patient-centered perspective now demands a nuanced understanding of the legal and temporal boundaries surrounding potential harm. This pivot from general knowledge to specific exposure concern sets the stage for examining how statutes of limitations, particularly in Michigan, apply to claims arising from Tysabri use and PML risk, without delving into mechanistic details.

Medical Evidence: PML Clinical Presentation and Diagnosis

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. While this mechanism reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance against JC virus, allowing reactivation and spread to the brain. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additional adverse effects include bleeding abnormalities, thrombocytopenia, and neonatal thrombocytopenia and anemia in exposed neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

The development of PML in Tysabri-treated patients is linked to three established risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibodies indicate prior exposure to JC virus, and their presence increases the risk of viral reactivation. Tysabri's inhibition of lymphocyte trafficking into the brain reduces the ability to control JC virus replication. Prior immunosuppressant use further compromises immune function, compounding the risk.

Adequacy of Warnings Regarding Tysabri and PML

The FDA-approved labeling includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also mandates that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution program designed to monitor patients for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, healthcare providers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers adequately communicated the risks to patients and whether the TOUCH program was properly implemented.

Settlement-Related Considerations for Affected Patients

For patients in Michigan who have developed PML after Tysabri treatment, legal claims may involve product liability, failure to warn, or negligence. The statute of limitations for personal injury claims in Michigan is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Given that PML symptoms may develop gradually and diagnosis can be delayed, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. Settlement considerations often include the severity of disability, medical expenses, lost income, and pain and suffering. Patients should consult with a qualified attorney to determine the applicable deadlines and to preserve their legal rights.

Timeline Between Exposure and Documented Harm

PML typically occurs after prolonged Tysabri exposure, with risk increasing significantly after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported earlier, especially in patients with additional risk factors. The latency period between JC virus reactivation and clinical symptoms can range from weeks to months. Once symptoms appear, the disease progresses rapidly, often leading to severe disability or death. The TOUCH program requires ongoing monitoring, but PML can still develop despite adherence to the program. Documenting the exact timeline of exposure, symptom onset, and diagnosis is critical for both medical management and legal claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Michigan?

In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. It is crucial to consult an attorney promptly to preserve your rights.

What are the risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors increase the likelihood of JC virus reactivation and PML development (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.